Production of Egoo consumables now established in China to support on-going clinical trials and future sales
Qlife Holding AB (publ) (“Qlife” or the “Company”) recently announced a restructuring and new financing to support its strategic goals. The Company is pleased to report that its operational plan with its partner Hipro Biotechnology (“Hipro”) in China is progressing as planned, with the production of Egoo consumables—EgooCapsule (Biochemistry reagents) and EgooCollect (Blood-to-Plasma filtration)—now established at the partner site. The target is to reach a capacity of 1 million in 2025 and 10 million within 3 years. This production capability will support clinical trial efforts and future